Central European Cooperative Oncology Group

🇦🇹Austria

Country: 🇦🇹Austria

Ownership: -

Established: 1999-01-01

Employees: -

Market Cap: -

Website: http://www.cecog.org/

Clinical Trials

Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 1

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Dacomitinib, Pemetrexed

First Posted Date: 2013-08-08

Last Posted Date: 2019-12-30

Lead Sponsor: Central European Cooperative Oncology Group

Target Recruit Count: 5

Registration Number: NCT01918761

Locations: 🇦🇹
Medizinische Universität Graz Klinische Abteilung für Onkologie, Graz, Austria
🇦🇹
Universitätsklinik für Innere Medizin I, Innsbruck, Austria

A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Lapatinib, Vinorelbine

First Posted Date: 2010-07-13

Last Posted Date: 2015-08-13

Lead Sponsor: Central European Cooperative Oncology Group

Target Recruit Count: 9

Registration Number: NCT01161368

Locations: 🇦🇹
Dep. of Medicine I , Division of Oncology, Vienna, Austria
🇭🇺
National Institute of Oncology, Budapest, Hungary

2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Biological: Bevacizumab and Capecitabine
Biological: Bevacizumab and Paclitaxel

First Posted Date: 2008-01-25

Last Posted Date: 2019-12-30

Lead Sponsor: Central European Cooperative Oncology Group

Target Recruit Count: 564

Registration Number: NCT00600340

Locations: 🇨🇿
Charles University Prague, Dep of Oncology, Prague, Czechia
🇵🇱
Centrum Medyczne Poradnia Onkologiczna, Rzeszow, Poland
🇦🇹
Hospital Elisabethinen Linz, Linz, Austria

and more 52 locations

Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: FOLFOX4 (Oxaliplatin), Cetuximab

First Posted Date: 2007-05-28

Last Posted Date: 2016-02-18

Lead Sponsor: Central European Cooperative Oncology Group

Target Recruit Count: 151

Registration Number: NCT00479752

Locations: 🇭🇷
University Hospital Centre Rijeka, Rijeka, Croatia
🇬🇷
General Hospital of Athens, Athens, Greece
🇭🇺
Semmelweis Univ. Radiology Clinic, Budapest, Hungary

and more 21 locations

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

Phase 3

Terminated

Conditions: Renal Cell Cancer

Interventions: Drug: Capecitabine, Interferon, Interleukin

First Posted Date: 2006-04-06

Last Posted Date: 2012-05-16

Lead Sponsor: Central European Cooperative Oncology Group

Target Recruit Count: 172

Registration Number: NCT00311467

Locations: 🇦🇹
Univ. Klinik f. Innere Medizin, Abt. Onkologie, Vienna, Austria

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Zometa

First Posted Date: 2006-02-22

Last Posted Date: 2012-05-01

Lead Sponsor: Central European Cooperative Oncology Group

Target Recruit Count: 376

Registration Number: NCT00294437

Locations: 🇷🇸
Clinical Center, Nis, Serbia
🇭🇷
GH, Dep Oncology and Reumatology, Varazdin, Croatia
🇭🇷
Clinical Hospital, Zagreb, Croatia

and more 51 locations

Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Gemcitabine, Docetaxel

First Posted Date: 2006-02-22

Last Posted Date: 2011-06-23

Lead Sponsor: Central European Cooperative Oncology Group

Target Recruit Count: 430

Registration Number: NCT00294385

Locations: 🇱🇧
Rizk Hospital, Beirut, Lebanon
🇸🇰
Nomocnica Sv. Alzbety, Narodny Onkologicky Ustav, Bratislava, Slovakia
🇮🇱
Rambam Medical Center, Oncol. Dep, Haifa, Israel

and more 14 locations

An Open, Randomized, Multicentre, Phase II Pilot Study

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Docetaxel

First Posted Date: 2006-02-17

Last Posted Date: 2011-06-23

Lead Sponsor: Central European Cooperative Oncology Group

Target Recruit Count: 37

Registration Number: NCT00293085

Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors

Phase 3

Completed

Conditions: Gastrointestinal Stromal Tumors

First Posted Date: 2006-02-17

Last Posted Date: 2015-08-13

Lead Sponsor: Central European Cooperative Oncology Group

Target Recruit Count: 125

Registration Number: NCT00293124

Locations: 🇦🇹
AKH, Universitätsklinik für Innere Medizin 1, Vienna, Austria
🇧🇦
Institute of Oncology Sarajevo, Sarajevo, Bosnia and Herzegovina
🇧🇬
SBALO National Oncology Center, Sofia, Bulgaria

and more 13 locations

Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2006-02-15

Last Posted Date: 2012-05-01

Lead Sponsor: Central European Cooperative Oncology Group

Target Recruit Count: 50

Registration Number: NCT00291850

Locations: 🇦🇹
AKH, Universitätsklinik für Innere Medizin 1, Vienna, Austria
🇵🇱
Klinika Chirurgii Instytutu Gruzlicy i Chorob Pluc, Warszawa, Poland
🇭🇺
Somogy Country Pulmo and Cardio Hospital,, Mosdos, Hungary

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy